SCHEMBL30764745

SCHEMBL30764745

COc1ccccc1CCCN1CC2(C1)CN(C(=O)Cc1ccc(Cl)cc1)C2

nearest known ligand 0.53

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
SIGMAR1 Q99720 4/20 0.53
KDM4E B2RXH2 2/20 0.48
ALOX15 P16050 1/20 0.48
ALDH1A1 P00352 1/20 0.48
KMT2A Q03164 2/20 0.43
HSD11B1 P28845 1/20 0.43
CYP2C19 P33261 1/20 0.43
MEN1 O00255 1/20 0.43
CYP2D6 P10635 2/20 0.42
CNR1 P21554 1/20 0.41
DRD4 P21917 1/20 0.41
CCR8 P51685 1/20 0.41
KCNH2 Q12809 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30764728 0.83 SIGMAR1 (0.60) SIGMAR1ALDH1A1HSD11B1
SCHEMBL30764749 0.80 HSD11B1 (0.49) SIGMAR1KMT2AHSD11B1CYP2C19MEN1
SCHEMBL30764719 0.79 SMN1; SMN2 (0.53) SIGMAR1ALDH1A1HSD11B1
SCHEMBL30764734 0.75 KMT2A (0.54) KMT2AHSD11B1MEN1KCNH2
SCHEMBL30764724 0.75 HSD11B1 (0.51) KDM4EALDH1A1KMT2AHSD11B1CYP2C19
SCHEMBL30764720 0.75 SIGMAR1 (0.60) SIGMAR1ALDH1A1HSD11B1
SCHEMBL30764705 0.75 EPHX2 (0.45) KDM4EALOX15ALDH1A1KMT2AHSD11B1
SCHEMBL30764707 0.74 HSD11B1 (0.55) SIGMAR1KDM4EALDH1A1KMT2AHSD11B1
SCHEMBL30764756 0.74 HSD11B1 (0.47) KDM4EALDH1A1KMT2AHSD11B1MEN1
SCHEMBL30764764 0.73 ALDH1A1 (0.49) SIGMAR1KDM4EALDH1A1HSD11B1CNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568968-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Remynd N.V. (BE) 2025-06-18 EP disclosed
WO-2024033479-A1 (AZA)SPIROHEPTANE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS REMYND N.V. (BE) 2024-02-15 WO disclosed